Castle Biosciences To Present New Data Showing DecisionDx-Melanoma Test Refines Mortality Risk Within AJCC Stages For Patients With Cutaneous Melanoma At 2026 AAD Annual Meeting
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC)

































